Denver (February 20, 2018) - NanoSphere Health Sciences will feature in a B-TV episode, airing Saturday, Feb. 24, and Sunday, Feb. 25, designed to give investors an insight into the company’s nanotechnology. The feature-length segment will highlight the NanoSphere Delivery System, an method of nanoencapsulating active ingredients to allow them to pass through five layers of skin, across the blood-brain barrier and into system circulation, according to a press release.
Topics discussed will include long-term expansion plans, the NanoSphere business model, the significance of having a disruptive technology and the financial status of the company to give investors a detailed view of NanoSphere Health Sciences and help them grow their portfolio.
The episode will visit the NanoSphere Health Sciences team at the facility, including David Sutton, president and COO, and Dr. Richard Kaufman, chief science officer and inventor of the NanoSphere Delivery System, and will introduce the viewer to the company’s cannabis product–-the award-winning Transdermal NanoSerum. NanoSerum is the world’s first and only clinically-tested transdermal cannabis product to provide relief for pain and anxiety in mere minutes compared to hours with other alternative consumption and ingestion methods.
“This B-TV episode gives us the opportunity to get in front of valued investors and financial audiences so they can learn more about our groundbreaking technology,” said David Sutton, COO and president of NanoSphere Health Sciences. “What NanoSphere offers is the first adaptable, nanoparticle delivery system platform that is commercially available for improving the efficacy of a wide range health care products across sectors. Our current product and disruption of the cannabis industry is only the beginning.”
The episode will be available to view on b-tv.com. BTV-Business Television, a weekly investor program, is Canada’s longest running business show and features emerging companies and top analysts across the US and Canada. Watch the promo for more information about the upcoming NanoSphere feature.
NanoSphere Health Sciences is listed on the Canadian Stock Exchange (CSE: NSHS). Their product pipeline includes intra-nasal and intra-oral adaptations of their technology. NanoSphere is currently licensing in Colorado and recently announced a licensing agreement in California. NanoSphere Health Sciences will further license its intellectual property and proprietary manufacturing method on a state-by-state basis and abroad, and is currently in discussions with operators in several states to replicate the business model in Colorado. Other planned future deployments include nutraceuticals, nonsteroidal anti-inflammatory drugs and animal health applications.
Top photo courtesy of NanoSphere Health Sciences
